Report initial proof-of-concept data for the CEDAR clinical trial

Not delivered by the deadline

AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.

Announced: 10 Nov 2021
Due: 31 Dec 2022
Checked: 2 Oct 2026

Deadline
Met
Late
Not met
Today

What the company said

“expects to report initial proof-of-concept data by the end of 2022”

SourceLENZ Therapeutics, Inc. Form 8-K press release, 2021-11-10
FilingSEC filing index
Deadline as statedby the end of 2022
Deadline used31 Dec 2022, the last day of the stated period
TypeProject
Permanent referenceKI-C-2021-LENZ-003341
Cite as https://keptindex.org/c/KI-C-2021-LENZ-003341/ — this address never changes.

What we found

Evidence strength A What the grades mean

The company did not report the CEDAR clinical trial proof-of-concept data by the end of 2022, and subsequently announced a voluntary pause of the study in January 2023.

A
LENZ Therapeutics, Inc. 10-K filed 2023-03-20 Regulatory filing · published 20 Mar 2023 · retrieved 2 Oct 2026 · kept permanently by the SEC · fingerprint ed0ffdf8a10c
“In January 2023, we announced a voluntary pause of our Phase 1/2 CEDAR study of nula-cel for SCD due to a serious adverse event in the first patient dosed” ✓ confirmed on the page

Market reaction: the shares moved -5.4% against the S&P 500 over the three sessions around the disclosure (17 Mar 2023 to 22 Mar 2023). What this measures

Checked 2 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

Deadline drift +181 days
3 versions

Version 1 · original · stated 10 Nov 2021

Deadline 31 Dec 2022 (“by the end of 2022”) · wording expected
Version 2 · stated 21 Mar 2022

Deadline 31 Dec 2023 (“2023”) · wording expected

“with initial proof-of-concept data anticipated in 2023”
Source for this version
Version 3 · stated 9 Nov 2022

Deadline 30 Jun 2023 (“mid-2023”)

“We continue to enroll patients in CEDAR and look forward to reporting initial clinical proof-of-concept data in mid-2023”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical readout
Indicative materiality: Medium rules
Action: Report
Deliverable: Initial proof-of-concept data for CEDAR trial
Language: Expected (“expects”, “plans”)
In the company’s control: Medium
Specificity: High

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Third check on a negative finding: disagreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and read it as “Withdrawn”, so a person decides.

Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works

Are you LENZ Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.